Arecor Limited's Sarah Howell talks to Proactive London about the announcement to expand their agreement with Hikma Pharmaceuticals PLC (LON:HKMA) to co-develop ready-to-administer injectable medicines in the US to a second product.
As Howell explains, this deal follows on from the first agreement signed in January to develop a product using Arecor’s proprietary drug formulation technology platform Arestat.
Howell hints that there could be a potential third deal in the pipeline considering the 'strength of this collaboration'.